NeurocrineNBIX
NASDAQ生物科技
關鍵指標
2,000 員工數100.58M 流通股本上市日期 1996-05-23
下次財報 ~2026年5月5日
關於 Neurocrine
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
最新新聞
展示全市場股票新聞
Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Neurocrine CFO Matt Abernethy sells $363,284 in NBIX shares
Treasury ETF shorts shift toward belly ahead of Fed decision
BoE to 'stand ready to hike', committee remains 'deeply divided'
The Fed’s interest rate decision in the epicenter of attention
News Flash: 70% of Wall Street Institutions Are Calling for at Least a 50-Basis-Point Fed Rate Hike in 2026
相關股票生物科技 產業
想看 NBIX 的即時 AI 觀點嗎?
啟動即時多智能體分析室 — Claude、GPT、Gemini、DeepSeek、Grok 和 Qwen 同時分析 NBIX,即時輸出訊號。